Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,865
archived clinical trials in
Multiple Sclerosis

Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
Patchogue, NY
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
Patchogue, NY
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
Raleigh, NC
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
Cleveland, OH
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
Columbus, OH
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
Medford, OR
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
Medford, OR
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
Portland, OR
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
Dallas, TX
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
Houston, TX
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
Mansfield, TX
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
Mansfield, TX
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
Round Rock, TX
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
Round Rock, TX
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
Norfolk, VA
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
Tacoma, WA
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Research Site
mi
from
Ciudad Autónoma de Buenos Aires,
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Research Site
mi
from
Ciudad Autónoma de Buenos Aires,
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
Hartford, CT
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
Hartford, CT
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
Port Orange, FL
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
Port Orange, FL
Click here to add this to my saved trials
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated:  1/12/2017
Research Site
mi
from
Wellesley, MA
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Status: Enrolling
Updated: 1/12/2017
Research Site
mi
from
Wellesley, MA
Click here to add this to my saved trials
Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extremities (EMST-LE) in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics
Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extremities (EMST-LE) in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics
Status: Enrolling
Updated:  1/31/2017
MS Center at Evergreen Health
mi
from
Kirkland, WA
Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extremities (EMST-LE) in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics
Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extremities (EMST-LE) in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics
Status: Enrolling
Updated: 1/31/2017
MS Center at Evergreen Health
mi
from
Kirkland, WA
Click here to add this to my saved trials
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated:  1/31/2017
Northwest NeuroSpecialists, PLLC
mi
from
Tucson, AZ
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated: 1/31/2017
Northwest NeuroSpecialists, PLLC
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated:  1/31/2017
University of Colorado
mi
from
Aurora, CO
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated: 1/31/2017
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated:  1/31/2017
Meridien Research
mi
from
Tampa, FL
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated: 1/31/2017
Meridien Research
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated:  1/31/2017
Fort Wayne Neurological Center
mi
from
Fort Wayne, IN
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated: 1/31/2017
Fort Wayne Neurological Center
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated:  1/31/2017
MidAmerica Neuroscience Institute
mi
from
Lenexa, KA
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated: 1/31/2017
MidAmerica Neuroscience Institute
mi
from
Lenexa, KA
Click here to add this to my saved trials
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated:  1/31/2017
QUEST Research Institute
mi
from
Bingham Farms, MI
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated: 1/31/2017
QUEST Research Institute
mi
from
Bingham Farms, MI
Click here to add this to my saved trials
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated:  1/31/2017
Great Falls Cllinic
mi
from
Great Falls, MT
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated: 1/31/2017
Great Falls Cllinic
mi
from
Great Falls, MT
Click here to add this to my saved trials
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated:  1/31/2017
Empire Neurology, PC
mi
from
Latham, NY
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated: 1/31/2017
Empire Neurology, PC
mi
from
Latham, NY
Click here to add this to my saved trials
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated:  1/31/2017
Winthrop University Hospital
mi
from
Mineola, NY
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated: 1/31/2017
Winthrop University Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated:  1/31/2017
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated: 1/31/2017
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated:  1/31/2017
Central Texas Neurology Consultants, P.A.
mi
from
Round Rock, TX
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Status: Enrolling
Updated: 1/31/2017
Central Texas Neurology Consultants, P.A.
mi
from
Round Rock, TX
Click here to add this to my saved trials
Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Incobotulinumtoxin Type A for the Functional Improvement of Lower Extremity Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  3/21/2017
Multiple Sclerosis Center of Northeastern New York
mi
from
Latham, NY
Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Incobotulinumtoxin Type A for the Functional Improvement of Lower Extremity Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 3/21/2017
Multiple Sclerosis Center of Northeastern New York
mi
from
Latham, NY
Click here to add this to my saved trials
Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers
An Open Label Study of the Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  3/21/2017
Multiple Sclerosis Center of Northeastern New York
mi
from
Latham, NY
Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers
An Open Label Study of the Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 3/21/2017
Multiple Sclerosis Center of Northeastern New York
mi
from
Latham, NY
Click here to add this to my saved trials
An Online Self-Guided Meditation Course for Individuals With Multiple Sclerosis
An Examination of Potential Neurochemical and Cognitive Mediators of the Relationship Between Mindfulness and Emotion Regulation in Individuals With Multiple Sclerosis: An Internet Based Self-Guided Pilot Study.
Status: Enrolling
Updated:  4/25/2017
Suffolk University
mi
from
Boston, MA
An Online Self-Guided Meditation Course for Individuals With Multiple Sclerosis
An Examination of Potential Neurochemical and Cognitive Mediators of the Relationship Between Mindfulness and Emotion Regulation in Individuals With Multiple Sclerosis: An Internet Based Self-Guided Pilot Study.
Status: Enrolling
Updated: 4/25/2017
Suffolk University
mi
from
Boston, MA
Click here to add this to my saved trials
Home Exercise Intervention in Persons With Multiple Sclerosis
Exercise, Subclinical Atherosclerosis and Walking Mobility in Multiple Sclerosis
Status: Enrolling
Updated:  5/1/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Home Exercise Intervention in Persons With Multiple Sclerosis
Exercise, Subclinical Atherosclerosis and Walking Mobility in Multiple Sclerosis
Status: Enrolling
Updated: 5/1/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluation of Coagulation in Multiple Sclerosis
A Cross-Sectional Study of Coagulation in Multiple Sclerosis
Status: Enrolling
Updated:  7/27/2017
Bastyr University Clinical Research Center
mi
from
Kenmore, WA
Evaluation of Coagulation in Multiple Sclerosis
A Cross-Sectional Study of Coagulation in Multiple Sclerosis
Status: Enrolling
Updated: 7/27/2017
Bastyr University Clinical Research Center
mi
from
Kenmore, WA
Click here to add this to my saved trials
Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis
Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis
Status: Enrolling
Updated:  8/29/2017
The Mayo Clinic
mi
from
Rochester, MN
Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis
Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis
Status: Enrolling
Updated: 8/29/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously Into Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/31/2017
Ageless Regenerative Institute LLC
mi
from
Aventura, FL
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously Into Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/31/2017
Ageless Regenerative Institute LLC
mi
from
Aventura, FL
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
Hope Research Institute Medical Plaza LLC Desert Hills
mi
from
Phoenix, AZ
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
Hope Research Institute Medical Plaza LLC Desert Hills
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
Multiple Sclerosis Center Drive, Neurology Suite 701
mi
from
Newport Beach, CA
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
Multiple Sclerosis Center Drive, Neurology Suite 701
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
University of Colorado at Denver Health and Sciences
mi
from
Denver, CO
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
University of Colorado at Denver Health and Sciences
mi
from
Denver, CO
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
Fort Collins Neurology
mi
from
Fort Collins, CO
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
Fort Collins Neurology
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
MS Center of Brevard MIMA Centry Research Associates
mi
from
Melbourne, FL
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
MS Center of Brevard MIMA Centry Research Associates
mi
from
Melbourne, FL
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
University of South Florida
mi
from
Tampa, FL
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
MS Center of Atlanta
mi
from
Atlanta, GA
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
MS Center of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
Bruce Hughes West Building
mi
from
Des Moines, IA
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
Bruce Hughes West Building
mi
from
Des Moines, IA
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
Research Site
mi
from
Rockland, MA
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
Research Site
mi
from
Rockland, MA
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
Michigan Neurology Associates P.C.
mi
from
Clinton, MI
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
Michigan Neurology Associates P.C.
mi
from
Clinton, MI
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
Henry Ford Hospital
mi
from
Detroit, MI
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated:  9/5/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Oral Cladribine in Early Multiple Sclerosis (MS)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
Status: Enrolling
Updated: 9/5/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials